Abstract
Iron is essential to life and is actively absorbed by enterocytes and secreted into plasma by the iron exporter ferroportin (SLC40A1). Dysregulation of iron homeostasis is a key component of many diseases such as hemochromatosis and beta-thalassemia. Ferroportin is the only known iron exporter protein, and as such is an important therapeutic target. To-date, modulators of ferroportin activity have shown promise in pre-clinical models, with recent screening assays enabling screening in a high throughput "loss of signal" format. Herein, we describe the design and synthesis of a novel BODIPY-labelled minihepcidin peptide to enable the high content analysis of ferroportin (SLC40A1) pharmacology, and the high throughput screening of compounds in a "gain of signal" assay format.
| Original language | English |
|---|---|
| Pages (from-to) | 1564-1571 |
| Number of pages | 8 |
| Journal | MedChemComm |
| Volume | 7 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2016 |
| Externally published | Yes |